Medtronic pacemaker gives a sales boost

November 28, 2019

Medtronic is the world’s largest medical device company with a market capitalization of US. $148 billion. It gets 60% of its sales and profits outside North America.

Medtronic’s latest quarterly earnings released Nov. 19, 2019 beat analyst expectations. The bottom line was boosted by strong performance in its unit that makes surgical instruments, including pacemakers.  

Medtronic has been beefing up this part of its operations through acquisitions. In May, it bought Titan Spine Inc., a company that makes titanium spacers that are inserted between the vertebrae during spinal fusion surgery. The purchase complements an acquisition of Mazor Robotics at the end of 2018. Mazor is a specialist in robot-assisted spinal surgery. This type of surgery is a less invasive and more precise alternative to traditional open spine surgery.

Medtronic is also a dividend leader. It raised its dividend with the July payment for the 42nd year in a row. The new rate yields 1.95% at current prices.

A recent Barron’s article noted that Medtronic’s Micra pacemaker which provides pacing to a single heart chamber, can be made to treat a dual-chamber condition. Medtronic is applying for approval to do so. If it gets a go ahead it would mean sales to a much larger market.

The article said that success with Micra is an illustration of momentum at Medtronic, including a shift to faster growth and a 14-quarter string of positive earnings surprises. Medtronic continues to benefit from the trends of first world aging and emerging market growth.  These tailwinds are raising sales and profits to offer investors rising dividends, safety and growth.

Medtronic is a top holding of the Harvest Healthcare Leaders Income ETF (HHL-TSX, HHL.U-TSX).  As of Oct. 31, 2019, the ETF held 20 of the largest global healthcare companies with an average market capitalization of $169 billion CAD.

About 44 per cent of the ETF’s portfolio holdings are in pharmaceuticals, 19 per cent in biotechnology, 19% in healthcare equipment and supplies and 15 per cent are healthcare providers.

The holdings have an average dividend yield of 1.97% and a current distribution yield of 9.15% which is enhanced by Harvest’s covered call strategy. The ETF’s portfolio holdings also have a 5-year return on equity of 18.34% and the ETF has a management fee of 0.85%.

For more on Harvest Portfolios Group click here.

The views and/or opinions expressed in the blog are of a general nature and are for informational purposes only. Blog contents should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies. Investors should consult their investment advisor before making any investment decision. 

 

You may also like…

Disclaimer

You will usually pay brokerage fees to your dealer if you purchase or sell units of the Fund(s) on the TSX. If the units are purchased or sold on the TSX, investors may pay more than the current net asset value when buying units of the Fund(s) and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning units of an investment fund. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in these documents.

Certain statements in the Harvest Blog are forward looking Forward-looking statements (“FLS”) are statements that are predictive in nature, depend upon or refer to future events or conditions, or that include words such as “may,” “will,” “should,” “could,” “expect,” “anticipate,” “intend,” “plan,” “believe,” or  “estimate,” or other similar expressions. Statements that look forward in time or include anything other than historical information are subject to risks and uncertainties, and actual results, actions or events could differ materially from those set forth in the FLS.

FLS are not guarantees of future performance and are by their nature based on numerous assumptions, which include, amongst other things, that (i) the Fund can attract and maintain investors and have sufficient capital under management to effect their investment strategies, (ii) the investment strategies will produce the results intended by the portfolio managers, and (iii) the markets will react and perform in a manner consistent with the investment strategies. Although the FLS contained herein are based upon what the portfolio manager believe to be reasonable assumptions, the portfolio manager cannot assure that actual results will be consistent with these FLS.

Unless required by applicable law, Harvest Portfolios Group Inc. does not undertake, and specifically disclaim, any intention or obligation to update or revise any FLS, whether as a result of new information, future events or otherwise.

Subscribe to our newsletter and stay informed

Join Us & Stay Informed!

* indicates required

Your Preferences   (Please select all the ways you would like to hear from)


You are a *


Confirm *